High PSMA Predictive of Good Response to Radioisotope Therapy in Prostate Cancer
Uptake of a transmembrane protein, which is expressed by virtually all prostate cancers, on imaging could be a viable predictive biomarker of patient response to isotope-based therapy, according to data from the phase II TheraP trial. High baseline prostate-specific membrane antigen (PSMA) uptake on PET was predictive of a favorable response to treatment with lutetium-177 […]